Scientific Leader Job at Caribou Biosciences, Inc. in Berkeley, California endpts.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from endpts.com Daily Mail and Mail on Sunday newspapers.
June 16 – 3pm ET/12pm PT
Marlon Nichols is the founding partner at MaC Venture Capital and has invested in companies like Gimlet Media, MongoDB, Thrive Market, PlayVS, Fair, LISNR, Mayvenn, Blavity and Wonderschool. Chris Bennett, Wonderschool founder, will join Nichols on this episode of Extra Crunch Live to tell us about the Series A fundraising process and give feedback on live pitches from the audience. REGISTER HERE FOR FREE!
Extra Crunch Live: Emergence and Retail Zipline
June 23 – 3pm ET/12pm PT
Lotti Siniscalco has experience across the fintech landscape as both an operator and investor. She’s held positions at NerdWallet, Goldman Sachs, Ribbit Capital and now at Emergence, where she invests in early-stage software companies. One of those investments is Retail Zipline, founded by Melissa Wong. The company has raised nearly $40 million. The duo will walk us through Zipline’s early pitch deck and give their own feedback on startup pitches from the audience. REGIST
Subscribe
In the face of daunting global challenges, such as climate change and a catastrophic pandemic, it is evident that the world urgently needs science-based solutions to tackle society s greatest problems.
At the University of California, Berkeley, the next generation of emerging scholars and entrepreneurs will work to confront those challenges in the BakarBioEnginuity Hub (BBH), a new campus initiative that aims to launch the world-changing startups of today, while cultivating the innovative leaders of tomorrow. These innovators can launch their startups at BBH s Bakar Labs, a world-class incubator open to teams from around the world a space where anyone can leverage all that Berkeley has to offer.
Published: May 05, 2021
BERKELEY, Calif. (BUSINESS WIRE) Caribou Biosciences, Inc, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Andrew Guggenhime to its board of directors. Mr. Guggenhime is an accomplished biopharmaceutical industry leader with more than 20 years of experience.
“Andrew brings a wealth of financial, strategic, and operational leadership experience in both private and public healthcare company settings,” said Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer. “We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we continue to build the company and advance our pipeline of chRDNA-edited allogeneic cell therapies.”
- Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95
- Delivers First-Quarter Net Revenues of $13.010 Billion on a GAAP Basis, an Increase of 51.0 Percent on a Reported Basis; Adjusted Net Revenues Were $12.935 Billion
- First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.744 Billion, an Increase of 12.9 Percent on a Reported Basis, or 11.8 Percent on an Operational Basis; U.S. Humira Net Revenues Were $3.907 Billion, an Increase of 6.9 Percent; Internationally, Humira Net Revenues Were $960 Million, a Decrease of 8.3 Percent on a Reported Basis, or 12.6 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $574 Million; Global Rinvoq Net Revenues Were $303 Million